HUMASIS Co., Ltd.
205470.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$64.72B
Close$
$1514.73
43.1% downside
Current Fair Value
43.1% downsideOvervalued by 43.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $64.72 Billion |
|---|---|
| Enterprise Value | $15.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-689.9 |
| Beta | -0.09 |
| Outstanding Shares | 22,625,000 |
Return
| Return on Equity | -7.38% |
|---|---|
| Return on Assets | -4.66% |
| Return on Invested Capital | -10.67% |
Valuation & Multiples
| P/E Ratio | -4.15 |
|---|---|
| PEG | -4.84 |
| Price to Sales | 1.9 |
| Price to Book Ratio | 0.25 |
| Enterprise Value to Revenue | 0.49 |
| Enterprise Value to EBIT | -0.61 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.91 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About HUMASIS Co., Ltd.
64 employees
CEO: Seong-Gon Kim Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases,...